

Supplementary Table 9. Clinical and imaging findings associated with the progression-free survival: subgroup with FOLFOX/
FOLFIRI+cetuximab

	Univariable analysis			Multivariable analysis		
	Hazard ratio	95% CI	P-value	Hazard ratio	95% CI	P-value
Age (year)	1.024	0.979–1.071	0.305	–	–	–
Male sex	1.166	0.426–3.192	0.765	–	–	–
Serum CEA level (ng/mL)	1.000	1.000–1.000	0.984	–	–	–
Change in SWV value (%)	1.037	1.012–1.063	0.004*	1.031	1.005–1.058	0.018*
Non-responder (SD or PD)	3.807	1.325–10.94	0.013*	2.141	0.681–6.733	0.193
<i>KRAS</i> mutation	0.409	0.159–1.056	0.065	–	–	–
No. of CRLMs ≥5	1.066	0.433–2.626	0.890	–	–	–
Primary rectal cancer	1.636	0.584–4.587	0.349	–	–	–
Resection of primary cancer	0.463	0.145–1.482	0.195	–	–	–
Metachronous CRLM	2.100	0.453–9.736	0.343	–	–	–
Presence of lymph node metastasis of primary cancer	0.833	0.299–2.322	0.727	–	–	–

FOLFOX, 5-fluorouracil, leucovorin, and oxaliplatin; FOLFIRI, 5-fluorouracil, leucovorin, and irinotecan; CI, confidence interval; CEA, carcinoembryonic antigen; SWV, shear-wave velocity; SD, stable disease; PD, progressive disease; *KRAS*, Kirsten rat sarcoma virus; CRLM, colorectal liver metastasis.

*P<0.05.